The University of Southampton
University of Southampton Institutional Repository

The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma

The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma
The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma
The acquisition of N-glycosylation sites occupied by oligomannose-type glycans in the immunoglobulin complementarity-determining region (CDR) is an early clonal tumor-specific identifier of follicular lymphoma (FL). CDR-located N-glycosylation sites are also acquired in germinal-center-B-cell-like diffuse large B-cell lymphomas (GCB-DLBCL), but their significance is less defined. We used RNA-seq immunoglobulin assembly to determine the frequency and CDR location of the acquired N-glycosylation sites (AGS) in two large independent DLBCL cohorts. Composition of the glycans occupying the AGS was determined using liquid chromatography-mass spectrometry and correlated with cell-of-origin, FL signature (defined by EZB phenotype or BCL2 translocation), transcript profile, and clinical outcome. CDR-located AGS were observed in 41-46% of GCB-DLBCL but were rare in other DLBCL. Only CDR-located AGS of DLBCL with an FL signature were occupied by oligomannose-type glycans. These DLBCL were termed Mann-type DLBCL. Conversely, the AGS of the other DLBCL were either non-glycosylated or occupied by complex-type glycans. Mann-type status was an independent marker of short progression-free survival and overall survival. In contrast, the other GCB-DLBCL cases, including those with an FL signature but without AGS, had the best outcomes. Mann-type DLBCL overexpressed gene-sets of cell growth, survival, and cycling, and underexpressed proinflammatory and apoptotic pathways, irrespective of concomitant MYC translocations. Acquisition of Mann-type glycans is a highly selective environmental pressure, identifying an aggressive GCB-DLBCL type with an origin related to FL. The detection of AGS in the CDR of GCB-DLBCLs with an FL signature defines Mann-type DLBCLs, refines prognosis and marks a precise tumor interaction to block early therapeutically.
2473-9529
Tatterton, Dylan James
ea972585-da97-46b7-bbac-7025ff42e294
Newby, Maddy L.
750f2bf7-92fe-45ee-afdc-95d06dbaff18
Allen, Joel D.
c89d5569-7659-4835-b535-c9586e956b3a
Sale, Benjamin J.
9dead432-5956-4b59-9d10-9d9db8a10ba1
Chiodin, Giorgia
4b3e9525-b377-4d16-b69a-e05d2e7854fe
Duriez, Patrick J.
4cf499bc-007a-43b3-b180-d6e5dc3d151b
Butler, John
5132f0e2-f28d-412a-be9a-e97963b4c0ee
McCann, Katy J.
da5bded0-d922-4838-b2e2-69829d2d95aa
Scott, David W.
84279176-6b08-4fd2-94ea-edf32bcfb64f
Morin, Ryan D.
fd197e63-a955-482e-a5be-d5673dc7247f
Dreval, Kostiantyn
02552819-383b-43f5-9ec3-755dbe0a749f
Davies, Andrew J.
6289b5e8-da1b-4189-b7ff-ac6ecf147afb
Bryant, Dean
10ed83e8-8080-4d9c-bba5-df9d4eec3a10
Crispin, Max
cd980957-0943-4b89-b2b2-710f01f33bc9
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Tatterton, Dylan James
ea972585-da97-46b7-bbac-7025ff42e294
Newby, Maddy L.
750f2bf7-92fe-45ee-afdc-95d06dbaff18
Allen, Joel D.
c89d5569-7659-4835-b535-c9586e956b3a
Sale, Benjamin J.
9dead432-5956-4b59-9d10-9d9db8a10ba1
Chiodin, Giorgia
4b3e9525-b377-4d16-b69a-e05d2e7854fe
Duriez, Patrick J.
4cf499bc-007a-43b3-b180-d6e5dc3d151b
Butler, John
5132f0e2-f28d-412a-be9a-e97963b4c0ee
McCann, Katy J.
da5bded0-d922-4838-b2e2-69829d2d95aa
Scott, David W.
84279176-6b08-4fd2-94ea-edf32bcfb64f
Morin, Ryan D.
fd197e63-a955-482e-a5be-d5673dc7247f
Dreval, Kostiantyn
02552819-383b-43f5-9ec3-755dbe0a749f
Davies, Andrew J.
6289b5e8-da1b-4189-b7ff-ac6ecf147afb
Bryant, Dean
10ed83e8-8080-4d9c-bba5-df9d4eec3a10
Crispin, Max
cd980957-0943-4b89-b2b2-710f01f33bc9
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8

Tatterton, Dylan James, Newby, Maddy L., Allen, Joel D., Sale, Benjamin J., Chiodin, Giorgia, Duriez, Patrick J., Butler, John, McCann, Katy J., Scott, David W., Morin, Ryan D., Dreval, Kostiantyn, Davies, Andrew J., Bryant, Dean, Crispin, Max and Forconi, Francesco (2025) The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma. Blood Advances. (doi:10.1182/blood.2025029163).

Record type: Article

Abstract

The acquisition of N-glycosylation sites occupied by oligomannose-type glycans in the immunoglobulin complementarity-determining region (CDR) is an early clonal tumor-specific identifier of follicular lymphoma (FL). CDR-located N-glycosylation sites are also acquired in germinal-center-B-cell-like diffuse large B-cell lymphomas (GCB-DLBCL), but their significance is less defined. We used RNA-seq immunoglobulin assembly to determine the frequency and CDR location of the acquired N-glycosylation sites (AGS) in two large independent DLBCL cohorts. Composition of the glycans occupying the AGS was determined using liquid chromatography-mass spectrometry and correlated with cell-of-origin, FL signature (defined by EZB phenotype or BCL2 translocation), transcript profile, and clinical outcome. CDR-located AGS were observed in 41-46% of GCB-DLBCL but were rare in other DLBCL. Only CDR-located AGS of DLBCL with an FL signature were occupied by oligomannose-type glycans. These DLBCL were termed Mann-type DLBCL. Conversely, the AGS of the other DLBCL were either non-glycosylated or occupied by complex-type glycans. Mann-type status was an independent marker of short progression-free survival and overall survival. In contrast, the other GCB-DLBCL cases, including those with an FL signature but without AGS, had the best outcomes. Mann-type DLBCL overexpressed gene-sets of cell growth, survival, and cycling, and underexpressed proinflammatory and apoptotic pathways, irrespective of concomitant MYC translocations. Acquisition of Mann-type glycans is a highly selective environmental pressure, identifying an aggressive GCB-DLBCL type with an origin related to FL. The detection of AGS in the CDR of GCB-DLBCLs with an FL signature defines Mann-type DLBCLs, refines prognosis and marks a precise tumor interaction to block early therapeutically.

Text
2._Text_v2_ (1) - Accepted Manuscript
Restricted to Repository staff only
Request a copy
Text
2. Text_v2_
Restricted to Repository staff only
Request a copy

More information

Accepted/In Press date: 30 July 2025
e-pub ahead of print date: 2 September 2025

Identifiers

Local EPrints ID: 505566
URI: http://eprints.soton.ac.uk/id/eprint/505566
ISSN: 2473-9529
PURE UUID: 4729f6df-eaab-46c6-9e3e-9f7cc7caeb00
ORCID for Dylan James Tatterton: ORCID iD orcid.org/0000-0002-1453-7496
ORCID for Maddy L. Newby: ORCID iD orcid.org/0000-0003-0624-245X
ORCID for Joel D. Allen: ORCID iD orcid.org/0000-0003-2547-968X
ORCID for Benjamin J. Sale: ORCID iD orcid.org/0000-0003-3292-1886
ORCID for Giorgia Chiodin: ORCID iD orcid.org/0000-0002-1456-8997
ORCID for Patrick J. Duriez: ORCID iD orcid.org/0000-0003-1814-2552
ORCID for Dean Bryant: ORCID iD orcid.org/0000-0003-3163-608X
ORCID for Max Crispin: ORCID iD orcid.org/0000-0002-1072-2694
ORCID for Francesco Forconi: ORCID iD orcid.org/0000-0002-2211-1831

Catalogue record

Date deposited: 14 Oct 2025 16:35
Last modified: 21 Oct 2025 02:04

Export record

Altmetrics

Contributors

Author: Dylan James Tatterton ORCID iD
Author: Maddy L. Newby ORCID iD
Author: Joel D. Allen ORCID iD
Author: Benjamin J. Sale ORCID iD
Author: Giorgia Chiodin ORCID iD
Author: Patrick J. Duriez ORCID iD
Author: John Butler
Author: Katy J. McCann
Author: David W. Scott
Author: Ryan D. Morin
Author: Kostiantyn Dreval
Author: Andrew J. Davies
Author: Dean Bryant ORCID iD
Author: Max Crispin ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×